QUÉBEC CITY, July 18,
2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX: AEZ) (the "Company") today announced that final
Phase 2 results in endometrial cancer on its anticancer compound,
AEZS-108, will be presented during a poster session at the upcoming
17th International Meeting of the European Society of
Gynaecological Oncology ("ESGO"), to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy. The trial was conducted by the
German AGO Study Group and study centers in Bulgaria. AEZS-108, a targeted cytotoxic
peptide conjugate, is currently in Phase 1/2 programs in prostate
and bladder cancer, and has successfully completed Phase 2 trials
in endometrial and ovarian cancer.
| Abstract
#247: |
"AGO-GYN 5 - (Phase II) study with AEZS-108, a targeted
cytotoxic LHRH analog in patients with LHRH receptor positive
endometrial cancer", Wimberger P., Gorchev G., Hanker L.,
Stähle A., Hristamian A., Beckmann M.W., Dall P., Gründker C.,
Hilpert F., Sehouli J., Harter P., Taskova V., Emons G., AGO Study
Group, Germany |
| |
|
| Presenter: |
Pauline Wimberger, MD, Gynaecology and Obstetrics, University
of Duisburg-Essen, Essen, Germany |
| Poster Session: |
Poster Shift III |
| Date and time: |
September 14, 2011 / 7:00-8:00 am (local time) |
| Venue: |
Milan Convention Center, Milan, Italy |
About AEZS-108
AEZS-108 represents a new targeting concept in
oncology using a hybrid molecule composed of a synthetic peptide
carrier and a well-known chemotherapy agent, doxorubicin. Phase 2
studies for the treatment of endometrial and ovarian cancer have
been successfully completed, and Phase 1/2 trials are being
conducted in prostate and bladder cancer. AEZS-108 is the first
intravenous drug in a clinical study that directs the chemotherapy
agent specifically to
LHRH-receptor expressing tumors, resulting in
more targeted treatment with less damage to healthy tissue.
AEZS-108 has been granted orphan-drug designation by the FDA and
orphan medicinal product designation from the EMA for the treatment
of ovarian cancer. Aeterna Zentaris owns the worldwide rights to
AEZS-108.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug
development company currently investigating potential treatments
for various cancers including colorectal, multiple myeloma,
endometrial, ovarian, prostate and bladder cancer. The Company's
innovative approach of "personalized medicine" means tailoring
treatments to a patient's specific condition and to unmet medical
needs. Aeterna Zentaris' deep pipeline is drawn from its
proprietary discovery unit providing the Company with constant and
long-term access to state-of-the-art therapeutic options. For more
information please visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.